Puma Biotech (PBYI) Tops Q2 EPS by 9c

Puma Biotech (NASDAQ: PBYI) reported Q2 EPS of ($1.17), $0.09 better than the analyst estimate of ($1.26). Revenue for the quarter came in at $50.8 million versus the consensus estimate of $45.67 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• Worthington Industries (WOR) Misses Q4 EPS by 9c